Free Trial
NASDAQ:MRSN

Mersana Therapeutics Q2 2025 Earnings Report

Mersana Therapeutics logo
$7.04 +0.18 (+2.62%)
Closing price 08/5/2025 04:00 PM Eastern
Extended Trading
$5.50 -1.54 (-21.88%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mersana Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.18
Beat/Miss
N/A
One Year Ago EPS
N/A

Mersana Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$6.06 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mersana Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Mersana Therapeutics Earnings Headlines

GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.
See More Mersana Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mersana Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mersana Therapeutics and other key companies, straight to your email.

About Mersana Therapeutics

Mersana Therapeutics (NASDAQ:MRSN), a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

View Mersana Therapeutics Profile

More Earnings Resources from MarketBeat